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Abstract
Background: Human papillomavirus (HPV) and HIV are each responsible for a considerable burden of disease.
Interactions between these infections pose substantial public health challenges, especially where HIV prevalence is
high and HPV vaccine coverage low.
Methods: Between July 2005 and January 2006, a cross-sectional community-based survey in Mombasa, Kenya,
enrolled female sex workers using snowball sampling. After interview and a gynaecological examination, blood and
cervical cytology samples were taken. Quantitative real-time PCR detected HPV types and viral load measures.
Prevalence of high-risk HPV was compared between HIV-infected and -uninfected women, and in women with
abnormal cervical cytology, measured using conventional Pap smears.
Results: Median age of the 820 participants was 28 years (inter-quartile range [IQR] = 24-36 years). One third of
women were HIV infected (283/803; 35.2%) and these women were y more likely to have abnormal cervical
cytology than HIV-negative women (27%, 73/269, versus 8%, 42/503; P < 0.001). Of HIV-infected women, 73.3% had
high-risk HPV (200/273) and 35.5% had HPV 16 and/or 18 (97/273). Corresponding figures for HIV-negative women
were 45.5% (229/503) and 15.7% (79/503). After adjusting for age, number of children and condom use, high-risk
HPV was 3.6 fold more common in HIV-infected women (95%CI = 2.6-5.1). Prevalence of all 15 of the high-risk HPV
types measured was higher among HIV-infected women, between 1.4 and 5.5 fold. Median total HPV viral load was
881 copies/cell in HIV-infected women (IQR = 33-12,110 copies/cell) and 48 copies/cell in HIV-uninfected women
(IQR = 6-756 copies/cell; P < 0.001). HPV 16 and/or HPV 18 were identified in 42.7% of LSIL (32/75) and 42.3% of
HSIL (11/26) lesions (P = 0.98). High-risk HPV types other than 16 and 18 were common in LSIL (74.7%; 56/75) and
HSIL (84.6%; 22/26); even higher among HIV-infected women.
Conclusions: HIV-infected sex workers had almost four-fold higher prevalence of high-risk HPV, raised viral load
and more precancerous lesions. HPV 16 and HPV 18, preventable with current vaccines, were associated with
cervical disease, though other high-risk types were commoner. HIV-infected sex workers likely contribute
disproportionately to HPV transmission dynamics in the general population. Current efforts to prevent HIV and
HPV are inadequate. New interventions are required and improved implementation of existing strategies.
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Human papillomavirus (HPV) is the most common
sexually transmitted infection (STI) worldwide. It is the
pre-eminent etiologic agent of cervical cancer, the sec-
ond most common cancer among women [1]. Over 100
HPV types have been identified, about 20 of which are
termed high-risk types, because of their propensity to
disrupt control of normal cell-cycles and thereby foment
the development of cervical malignancy [2]. In addition
to cervical neoplasia, HPV is also causally associated
with anogenital, oropharyngeal and some skin cancers
[3,4]. HIV, another STI with extensive public health
impact [5], shares many common behavioural risk fac-
tors with HPV and the infections interact in important
ways. Female sex workers (FSW) have a particularly
high risk for both HIV and HPV infection, and the
interactions between these infections are especially pro-
nounced in this population group [6-8].
Women with HIV infection commonly have a broader
range of HPV genotypes, often with multiple concurrent
HPV infections [9]. HIV disease influences the natural
history of HPV by increasing the likelihood of persistent
infection and virulence, and hastening the time-course
of HPV disease [10]. Thus, compared with HIV-negative
women, HIV-positive women are more likely to progress
to cervical cancer, have a worse prognosis and a higher
risk of recurrence [11-13]. It is also important to note
that the interplay between HIV and HPV infection, and
the consequences thereof are influenced by other factors
such as age, sexual practices and socio-economic char-
acteristics of women [14-16].
Besides the effects of HIV on the natural history of
HPV infection, it is possible that HIV affects the trans-
missibility of HPV, and even possibly vice versa [17-19].
Causality, and the potential bidirectional nature thereof,
cannot yet be definitively determined from available,
mostly cross-sectional evidence. It remains plausible,
however, that enhanced friability and the recruitment of
CD4 and dendritic cells with HPV infection increases
susceptibility to HIV acquisition in a manner similar to
other genital tract infections such as Neisseria
gonorrhoea.
The HPV vaccine, including high-risk HPV types 16
and 18, is effective in reducing HPV infection and HPV-
related disease in women, and potentially in men [20].
These vaccines are increasingly becoming available in
resource-constrained settings [21], which carry the over-
whelming burden of HPV disease. Additional informa-
tion about the prevalence of high-risk HPV types and
their relative contribution to cervical disease in this set-
ting would assist in planning for vaccine implementation
and future development. This study assesses the preva-
lence of high-risk HPV types and HIV among FSW in
Mombasa, Kenya, and the associations between these
infections and with other demographic and behavioural
variables. Additionally, the complex inter-relationships
between type-specific HPV viral load, HIV infection and
cervical cytology are evaluated.
Methods
Setting and population
Mombasa, in Kenya’s Coast province, is a major eco-
nomic centre in the region, with important tourism, port,
rail and industrial enterprises, as well as a large FSW
population. Sex workers in Mombasa are working either
full- or part-time from bars, hotels, streets or from their
homes [22,23]. About a third are involved in other small
businesses, including selling foodstuffs, vegetables and, in
some areas, local brew on the roadside [23]. Commonly
the clients of sex workers are employed at local factories
or are matatu (minibus taxi) touts or drivers.
Study Design
Between July 2005 and January 2006, 820 FSW from
Chaani and Kisauni divisions of Mombasa were enrolled
in a community-based, cross-sectional survey. FSW were
recruited using snowball sampling, a method appropri-
ate for locating difficult-to-reach populations, particu-
larly those with stigmatized behaviours or professions
[24]. Full details of study methodology are provided
elsewhere [23]. In brief, initial respondents were identi-
fied from bars, guest houses and the street, with subse-
quent participants recruited using snowball sampling.
To limit the potential for friendship bias, we restricted
the maximum number of women recruited through one
participant to 10. Eligible participants were self-reported
FSW, older than 16 years and working within Kisauni or
Chaani. For this study, sex workers were defined as any
woman who reported having received money or gifts in
exchange for sex in the past year. The Kenyatta National
Hospital Ethics and Review Committee reviewed and
provided approval for the study procedures.
Study procedures
In the two study areas, an existing drop-in centre for
FSW and a municipality run health centre were modi-
fied to include clinical examination areas and related
research facilities. Here staff obtained written informed
consent, collected demographic and behavioural data
using structured questionnaires, and offered HIV coun-
selling and same-day testing. Blood plasma samples
were taken and a gynaecological examination was done
with speculum insertion, and collection of endocervical
and high vaginal swabs.
Cervical samples were collected using a cervix brush
(Cervex-brush®, Rovers®, Oss, The Netherlands) and
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colaou (Pap) smears. Slides were read by a cytologist
with masters level training, supervised by a pathologist.
An external cytopathologist provided quality control.
T h eB e t h e s d aR e p o r t i n gS y stem was used for cytologic
classification [25]. The cervix brush tips were preserved
in a liquid-based cytology collection medium (SurePath®,
Tripath Imaging Inc., Burlington, North Carolina, USA)
and stored at 4°C until further processing.
HPV testing was done as described by Depuydt et al
[26] in an accredited laboratory (ISO certification:
ISO15189). Briefly, HPV DNA was extracted from exfo-
liated cervical cells using the standard proteinase K-
based digestion protocol, following the manufacturer’s
instructions. Cells were incubated with proteinase K
solution (100 μg/ml) for 3 hours at 55°C. DNA was then
further purified by spin column chromatography. HPV
types were determined using a series of real-time PCR
reactions with specific primers and TaqMan® (Invitro-
gen, La Jolla, USA) probes for high-risk HPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68
[2]. Low-risk HPV types 6 and 67 were also detected.
A parallel testing algorithm was used for HIV diagno-
sis using rapid immunoassays: Uni-Gold™ Recombigen®
HIV (Trinity Biotech plc, Bray, Ireland) and Determine®
H I V - 1 / 2( A b b o t tJ a p a nc oL t d ,M i n a t o - K u ,T o k y o ,
Japan). In the case of indeterminate results, an enzyme-
linked immunosorbent assay was used to confirm HIV
status.
Where indicated, FSW received STI treatment free of
charge. Women with a positive HIV test were referred
to a nearby HIV clinic where medical care and antire-
troviral treatment are provided, with no user fees.
Women with abnormal cervical cytology were referred
for further management and follow-up at the provincial
teaching and referral hospital (Coast Provincial General
Hospital, Mombasa) or a local municipal clinic sup-
ported by the International Centre for Reproductive
Health.
Data management and analysis
Data were double entered by separate data clerks. Fol-
lowing data checking and cleaning, analysis was done
using Intercooled Stata, version 10.0 (Stata Corporation,
College Station, TX, USA). The presence of any detect-
able viral load for specific HPV types was considered
diagnostic for infection with that specific type. Chi-
square tests were used to detect differences in HPV pre-
valence in women with and without HIV infection. For
each HPV type, the Mann-Whitney U test was used to
compare the HPV viral load of HIV infected and unin-
fected women who had ≥ 1 HPV copy/cell. Total HPV
viral load was also calculated for each woman (the sum
of the viral load of each high-risk HPV infection). To
account for differences in age distribution between HIV
infected and uninfected women, age-adjusted risk ratios
are presented comparing the risk of HPV infection in
these two groups. A multivariable logistic regression
model was constructed, in which the presence of any
high-risk HPV infection was the dependent variable. Fit-
ting of the regression model was done using stepwise
backward elimination, with variables retained if their
removal markedly altered model parameters [27]. Vari-
ables associated with high-risk HPV in univariate analy-
sis (P <0 . 1 )w e r ei n c l u d e di nt h ei n i t i a lm o d e l .
Associations between high-risk HPV infection and
abnormal cervical cytology were also assessed.
Results
Socio-demographic and sexual behaviour characteristics
The median age of the 820 enrolled FSW was 28 years
(IQR = 24-36 years; table 1). The vast majority were
currently single, either never been married (346/818;
42.3%) or separated (33.0%, 270/818), divorced (13.0%,
106/818) or widowed (8.9%, 73/818). Women had a
median of two children (IQR = 1-3 children).
Women obtained clients mainly at bars or nightclubs
(70.7%, 580/820), though about a fifth worked mainly
from home (163/820). The median income from sex
work per week was 14.3 US$ (IQR = 8.1-27.0 US$;
exchange rate of US$1 = 74 Kenya shillings), obtained
from a mean of 2.3 sex partners per week (standard
deviation (sd) = 0.7). About two thirds of women
reported consistently using a condom with clients
(63.2%, 518/820), while consistent condom use with
boyfriends was reported by only 92 of 437 women who
currently had a boyfriend (21.1%).
Prevalence of HIV
A third of participants were HIV infected (283/803;
35.2%); HIV status was unknown in 17 women. Com-
pared to HIV-negative women, infected women were a
median 3 years older. With each increase in decade of
age, the odds of HIV infection increased 1.6 fold (95%CI
=1 . 4 - 2 . 0 ;P < 0.001). Prevalence of HIV was lower in
Muslim (25.4%, 58/228) than in other women (39.1%,
225/575; P < 0.001) and women with a shorter duration
of sex work (median 4 years [IQR = 2-7] for HIV-nega-
tive women versus median 5 years [IQR = 3-9] for posi-
tive women; P = 0.002). HIV prevalence was also higher
in widowed women (62.9%, 44/70 compared with 32.6%,
238/731 in other women; P < 0.001) and in those with a
recent genital sore (42.3%, 66/156 versus 33.6%, 217/646
in women without history of genital sores; P = 0.04).
Prevalence of HPV infection
Of the 820 participants, study samples of adequate qual-
i t yw e r eo b t a i n e df r o m7 8 6w o m e nf o rP a ps m e a r
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Page 3 of 10Table 1 Distribution of demographics and sexual behaviour by HIV status and presence of high-risk HPV infection
among female sex workers in Mombasa Kenya
HIV-negative women HIV-positive women
Variable All women No high-risk
HPV
High-risk
HPV
P No high-risk
HPV
High-risk
HPV
P
Age n/N (%)
17-24 232/817 (28.4) 81/272 (29.8) 88/229 (38.4) 13/73 (17.8) 38/199 (19.1)
25-29 216/817 (26.4) 72/272 (26.5) 64/229 (28.0) 14/73 (19.2) 54/199 (27.1)
30-39 246/817 (30.1) 84/272 (30.9) 55/229 (24.0) 28/73 (38.4) 68/199 (34.2)
≥40 123/817 (15.1) 35/272 (12.9) 22/229 (9.6) 0.02† 18/73 (24.7) 39/199 (19.6) 0.26†
median years (IQR)
¥ 28 (24-36) 28 (23-35) 27 (22-32) 0.02 32 (27-39) 30 (26-38) 0.27
Religion n/N (%)
Catholic 255/820 (31.1) 76/274 (27.7) 67/229 (29.3) 26/73 (35.6) 77/200 (38.5)
Muslim 236/820 (28.8) 89/274 (32.5) 78/229 (34.1) 12/73 (16.4) 42/200 (21.0)
Protestant 313/820 (38.2) 101/274 (36.9) 78/229 (34.1) 34/73 (46.6) 80/200 (40.0)
Other 16/820 (2.0) 8/274 (2.9) 6/229 (2.6) 0.92 1/73 (1.4) 1/200 (0.5) 0.62
Education level n/N (%)
Never attended school 82/820 (10.0) 33/274 (12.0) 17/229 (7.4) 6/73 (8.2) 22/200 (11.0)
Primary school 513/820 (62.6) 164/274 (59.9) 148/229 (64.6) 45/73 (61.6) 128/200 (64.0)
Secondary school 202/817 (24.8) 67/274 (24.5) 57/229 (24.9) 20/73 (27.4) 49/200 (24.5)
Tertiary education 22/817 (2.7) 10/274 (3.7) 7/229 (3.1) 0.35 2/73 (2.7) 1/200 (0.5) 0.38
Marital status n/N (%)
Never married 346/818 (42.3) 113/274 (41.2) 109/228 (47.8) 25/73 (34.3) 78/199 (39.2)
Married or cohabitating 23/818 (2.8) 15/274 (5.1) 4/228 (1.8) 0/0 (0) 5/199 (2.5)
Separated, divorced or widowed 449/818 (54.9) 147/274 (53.7) 115/228 (50.4) 0.07 48/73 (65.8) 116/199 (58.3) 0.26
Number of live children n/N (%)
0 114/819 (13.9) 39/274 (14.7) 29/229 (12.7) 16/73 (21.9) 18/199 (9.1)
1 223/819 (27.2) 66/274 (25.1) 78/229 (34.1) 10/73 (13.7) 60/199 (30.2)
2-3 331/819 (40.4) 119/274 (41.9) 85/229 (37.1) 29/73 (39.7) 82/199 (41.2)
≥4 151/819 (18.4) 50/274 (18.4) 37/229 (16.2) 0.11 18/73 (24.7) 39/199 (19.6) 0.004
Workplace n/N (%)
Bar or nightclub 580/820 (70.7) 179/274 (65.3) 167/229 (72.9) 52/73 (71.2) 149/200 (74.5)
Home 163/820 (19.9) 63/274 (23.0) 44/229 (19.2) 14/73 (19.2) 33/200 (16.5)
Street 54/820 (6.6) 23/274 (8.4) 10/229 (4.4) 4/73 (5.5) 16/200 (8.0)
Hotel, guest house or other 23/820 (2.8) 9/274 (3.3) 8/229 (3.5) 0.17 3/73 (4.1) 2/200 (1.0) 0.31
Age started sex work mean years (sd) | 23.9 (6.8) 23.7 (6.4) 22.6 (6.7) 0.07 25.6 (7.0) 25.3 (7.2) 0.73
Duration of sex work median years (IQR)
¥ 4 (2 - 8) 4 (2-8) 4 (2-7) 0.51 6 (3-10) 5 (3-8) 0.24
Number of partners median in past week
(IQR)
¥
3 (2 - 6) 3 (2-6) 3 (2-6) 0.59 3 (2-5) 3 (1-6) 0.80
Condom use at last sex with client n/N (%) 661/819 (80.7) 210/273 (76.9) 195/229 (85.2) 0.02 58/73 (79.5) 161/200 (80.5) 0.85
Condom use (clients) n/N (%)
Never 17/820 (2.1) 11/274 (4.0) 3/229 (1.3) 1/73 (1.4) 1/200 (0.5)
Inconsistent 285/820 (34.8) 102/274 (37.2) 78/229 (34.1) 28/73 (38.4) 62/200 (31.0)
Always 518/820 (63.2) 161/274 (58.8) 148/229 (64.6) 0.12 44/73 (60.3) 137/200 (68.5) 0.37
Chi
2 test unless indicated.
¥ Mann-Whitney U test; † chi-square test for trend; | Student’s t test^ Infection with HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56,
58, 59, 66 and 68 defined as high-risk HPV infection
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than half of FSW were infected with high-risk HPV
(55.6%; 439/789). Among these women, over half had at
least two different high-risk HPV types (54.9%; 241/
439). HPV types 16 and/or 18 were detected in 22.8% of
women (180/789), but more than twice as many were
infected with high-risk HPV types other than 16 and 18
(48.5%, 383/789). A quarter of women were infected
with low-risk HPV type 6 and/or 67 (194/789).
Co-infection with both HIV and high-risk HPV
occurred in 25.8% (200/776) of FSW (table 2). High-risk
HPV was detected in 73.3% (200/273) of HIV-infected
women versus 45.5% (229/503) of uninfected women,
with an age-adjusted risk ratio (RR) of 1.7 (95%CI RR =
1.5-1.9; P < 0.001). Co-infection with two or more high-
risk HPV types was more frequent among HIV positive
than negative women (48.7%, 133/273 versus 20.4%,
103/506; P < 0.001). Fifteen percent of HIV-infected
FSW had four or more high-risk HPV types.
Predictors of high-risk HPV infection
Among the whole study population, age was not asso-
ciated with prevalence of high-risk HPV. However, in
HIV-negative women, age effects were noted. Here,
HPV prevalence decreased with increasing age, for
example, 52.1% of HIV-negative women aged 17-24
years had high-risk HPV (88/169) while this figure was
38.6% in women older than 40 years (22/57, P = 0.02;
chi-square test for trend). Similarly, a linear decrease in
the prevalence of HPV 16 and/or HPV 18 was noted in
HIV-negative women, from a prevalence of 40.5% (32/
169) in women below 25 years to 7.6% (6/57) in women
above 40 years (odds of infection decreased by 0.71 with
each increase in decade of age, 95%CI = 0.52-0.96; P =
0.03, chi-square test for trend). Among women with
HIV infection, the prevalence of HPV 16 and/or HPV
18 did not vary across age groups.
When adjusted for age, having a child and condom
use, HIV status remained a predictor for high-risk HPV
infection (adjusted odds ratio [AOR] = 3.6; 95%CI =
2.6-5.1; P < 0.001; table 3). Having one or more children
was also independently associated with high-risk HPV;
these women had a 2.0 fold higher odds of high-risk
HPV (95%CI AOR = 1.3-3.3; P = 0.003) than women
with no children. High levels of reported condom use
were not protective against high-risk HPV infection, nor
were other measures of sexual behaviour or sex work
duration associated with HPV prevalence.
Effect of HIV status on prevalence of specific high-risk
HPV types
Type-specific analysis showed that the most prevalent
HPV types were similar in HIV-positive and -negative
women. In decreasing order, the most prevalent high-
risk HPV types among HIV-positive women were 52,
16, 53, 18, 35 and 66, while for HIV-negative women
the order was HPV 16, 59, 35, 52, 66 and 53 (table 2).
Compared with HIV uninfected women, prevalence of
all HPV types was higher in HIV-infected women, with
the age-adjusted risk ratio a median 2.7 fold higher
(IQR RR = 2.1-3.7; range of RRs = 1.4-5.5). HPV 16
and/or HPV 18 infection was found in 35.5% (97/273)
of HIV-positive women and in 15.7% (79/503) of HIV-
negative women (P < 0.001).
HPV viral load
HIV infection was significantly associated with an ele-
vated HPV viral load for types 16, 31, 39, 45, 51, 52, 59
a n d6 6 .F o r9o ft h e1 5h i g h - r i s kH P Vt y p e sm e a s u r e d ,
the median viral load for high-risk HPV was 5 or more
times higher in HIV-positive than HIV-negative women.
The total HPV viral load was 16.9 times higher in
women with HIV infection compared to uninfected
women (median 811 copies/cell versus 48 copies/cell; P
< 0.001).
Cervical cytology
High-risk HPV was strongly associated with abnormal
cervical cytology, and was detected in 88.5% of women
with HSIL (23/26) and 82.7% with LSIL (62/75). HPV
type 16 and/or 18 was detected in 42.7% of women with
LSIL (32/75) and 42.3% with HSIL (11/26). However,
high-risk HPV types other than 16 and 18 were more fre-
quent, occurring in 74.7% of LSIL (56/75) and 84.6% of
HSIL (22/26), even more so among HIV-infected women
( 1 2o f1 3w o m e nw i t hH S I L ) .H i g h - r i s kH P Vt y p e5 2
(907 copies/cell) and low-risk type 67 were detected in
the woman who had invasive carcinoma on cytology.
Half of women with a normal Pap smear had high-risk
HPV (327/648), though high-risk HPV was more com-
mon among HIV-infected women with normal cytology
(67.4%; 130/193). Abnormal Pap smears were also mark-
edly more common in HIV-infected women, of whom
about 5% had HSIL (13/269) and 20% LSIL (54/269).
The corresponding figures for HIV-negative women
were 2.4% (12/503) and 4.2% (21/503), with one woman
having squamous cell carcinoma. The 13 HIV-infected
women with HSIL had a median of 3 high-risk HPV
infections (IQR = 2-3).
Of the 51 HIV-infected women whose total HPV viral
load was ≥10
4 copies/cell, 24 (47.1%) had LSIL and 6
had HSIL lesions (11.8%). Only 18 HIV-negative women
had a total HPV viral load = 10
4 copies/cell, of whom 4
had LSIL and 1 HSIL.
Discussion
In this study, about one-third of female sex workers
were infected with HIV and more than half with high-
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in Mombasa Kenya
Variable HIV-negative n/N (%) HIV-positive n/N (%) P Risk ratio
#
(95%CI)
Prevalence of high-risk HPV
Any high-risk HPV infection* N = 503 229 (45.5) N = 273 200 (73.3) <0.001 1.7 (1.5-1.9)
Type 16 56 (11.1) 66 (24.2) <0.001 2.4 (1.7-3.4)
Type 18 34 (6.8) 51 (18.7) <0.001 2.9 (1.9-4.6)
Type 31 31 (6.2) 33 (12.1) 0.004 2.0 (1.2-3.4)
Type 33 1 (0.2) 3 (1.1) 0.095 4.3 (0.41-45.8)
Type 35 39 (7.8) 49 (18.0) <0.001 2.7 (1.7-4.1)
Type 39 20 (4.0) 36 (13.2) <0.001 4.2 (2.3-7.5)
Type 45 18 (3.6) 21 (7.7) 0.012 2.3 (1.3-4.2)
Type 51 32 (6.4) 39 (14.3) <0.001 2.5 (1.5-4.1)
Type 52 38 (7.6) 70 (25.6) <0.001 3.7 (2.5-5.6)
Type 53 35 (7.0) 56 (20.5) <0.001 3.0 (2.0-4.6)
Type 56 24 (4.8) 39 (14.3) <0.001 2.9 (1.7-4.9)
Type 58 21 (4.2) 15 (5.5) 0.40 1.4 (0.7-2.7)
Type 59 43 (8.6) 36 (13.2) 0.04 1.7 (1.1-2.6)
Type 66 37 (7.4) 40 (14.7) 0.001 2.1 (1.3-3.3)
Type 68 2 (0.4) 6 (2.2) 0.02 5.5 (1.0-29.0)
Mean high-risk HPV types (sd) 0.8 (1.1) 1.8 (1.8) <0.001
Low risk HPV
Type 6 N = 503 13 (2.6) N = 273 10 (3.7) 0.40 1.4 (0.63-3.3)
Type 67 87 (17.3) 84 (30.8) <0.001 1.8 (1.4-2.4)
Viral load of high-risk HPV types (n≥1 copy/cell; median (IQR))
Type 16 38; 32.5 (4-472) 52; 145 (12-3278) 0.016
Type 18 18; 12 (4-58) 31; 31 (6-718) 0.23
Type 31 22; 15 (3-572) 25; 208 (58-13 257) 0.02
Type 33 1; 204 (NA) 3; 15 453 (251-45 601) 0.18
Type 35 34; 118 (14-4882) 48; 302 (61-9969) 0.11
Type 39 14; 13 (1-89) 25; 106 (3-2600) 0.06
Type 45 14; 8 (2-24) 21; 49 (4-252) 0.04
Type 51 30; 43 (3-1738) 37; 826 (34-43 983) 0.02
Type 52 31; 12 (3-71) 59; 76 (5-938) 0.05
Type 53 27; 5 (2-14) 47; 31 (1-288) 0.14
Type 56 20; 112 (5.5-829) 31; 219 (20-1511) 0.39
Type 58 12; 16 (4.5-67) 13; 7 (4-32) 0.81
Type 59 21; 27 (3-235) 20; 437 (20-3552) 0.04
Type 66 22; 4 (2-794) 35; 48 (7-1193) 0.07
Type 68 0; 0 1; 1; (NA) -
Total high-risk HPV viral load 48 (6-756) 811 (33-12 110) <0.001
Cervical cytology (Pap smear)
Normal N = 503 461 (91.7) N = 269 196 (72.9)
ASC-US/ASC-H 8 (1.6) 6 (2.2)
LSIL 21 (4.2) 54 (20.1)
HSIL 12 (2.4) 13 (4.8)
Invasive carcinoma 1 (0.2) 0 (0) <0.001
^Infection with HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68 defined as high-risk HPV infection. *Any detectable HPV viral load >0 copies/
cell considered diagnostic. #Age-adjusted risk ratio. LSIL low-grade intraepithelial lesion; HSIL high-grade squamous intra-epithelial lesion; ASC-US atypical
squamous cells of undetermined significance; ASC-H atypical squamous cells: cannot exclude high-grade squamous intra-epithelial lesion. Median copies/cell are
rounded to closest whole number. Vari. Cat. Variable category
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more than three times as common among HIV-positive
than negative women. Prevalence of high-risk HPV in
the study population is notably higher than in a meta-
analysis of HIV-infected women including 20 studies,
mostly from North America [28]. Though it is difficult
to make direct comparisons between studies as HPV
detection methods differ, the prevalence in this study is
similar to a recent study among HIV-infected female
hospital patients in Zambia [29]. Also of note, among
HIV-infected women who had normal cervical cytology,
two thirds had high-risk HPV infection in this study,
twice as many as the meta-analysis of HIV-infected
women [28]. Prevalence of high-risk HPV in HIV-nega-
tive FSW in our study is similar to previous reports
among sex workers in other settings, for example, 39%
in Spain [6], 43% in Mexico [30] and 48% in Japan [8],
though a study in Calcutta, India reported higher levels
(63%) [7].
Simultaneous infection with multiple HPV types was
more frequent in HIV-positive women. This finding is
consistent with previous reports [28], and according to
Chaturvedi et al [31], is attributable to the common
mode of transmission of HPV and HIV; the inability to
clear HPV infections; as well as reactivation of latent
HPV infections, the latter two occurring as a result of
immune suppression [9,32-34]. Similar factors may
underlie the concerning high levels of HPV 16 and 18
noted in older HIV-positive women in this study [35].
Though here, a particular ability of HPV 16 to evade
immune surveillance in HIV-positive women may
account for the high levels noted in all age groups [34].
Persistent HPV infection is the main cause of cervical
cancer, and since this is more common in HIV-infected
women, it makes the presence of cervical lesions in a
quarter of HIV-positive women in this study even more
concerning [36]. Many previous studies, including one
in Mombasa [37], have noted a higher prevalence of
HSIL among HIV-positive than HIV-negative women
[38-40].
Broadly, the distribution of high-risk HPV types were
similar in HIV-infected and uninfected women, albeit
that the most common HPV types occurred in slightly
differing order of prevalence. However, the most com-
mon HPV types in our study differ from those in other
settings [28,40]. These regional differences in HPV types
might, at least partly, be attributed to HIV and its differ-
ential effects on the natural history of specific types.
However, not all findings support this assertion [41].
An association between parity and high-risk HPV has
been noted previously, though might be accounted for
by confounding due to sexual behaviour, such as
unprotected sex or age at coital debut [6,35,42]. A large
multicentre case-control study suggests, however, that
full-term pregnancy is a cofactor that increases the risk
of progression from HPV infection to cancer [35]. This,
the authors speculate, might be due to hormonal
changes in the second and third trimester of pregnancy
or to increased cervical ectopy with multiparity. Possi-
bly, the reduction in cervical cancer noted worldwide
might be partly explained by the general global decline
in parity.
Age, as previously shown [6,30,43,44], is an important
predictor of HPV infection, with younger women being
more frequently infected. Again, the absence of age
effects among HIV-infected women in our study may be
explained by a decreased ability to clear HPV infection,
reactivation of HPV or re-infection with HPV types pre-
viously cleared, all of which likely occur more com-
monly in HIV-infected women.
Table 3 Association of HIV and other covariates with high-risk HPV infection: multivariable logistic regression analysis
Variable Unadjusted odds ratio
(95%CI)
Adjusted odds ratio
(95%CI)
P
Age
17-24 1.3 (0.80-2.0) 1.9 (1.1-3.2) 0.014
25-29 1.3 (0.83-2.1) 1.5 (0.92-2.5) 0.10
30-39 1.0 (0.66-1.7) 1.1 (0.69-1.7) 0.81
≥40 1.0 1.0
Have one or more children
No 1.0 1.0
Yes 1.5 (1.0-2.3) 2.0 (1.3-3.3) 0.003
Condom use with client at last sex
No 1.0 1.0
Yes 1.5 (1.0-2.1) 1.4 (0.96-2.1) 0.08
HIV infection
No 1.0 1.0
Yes 3.3 (2.4-4.5) 3.6 (2.6-5.1) <0.001
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lysis by De Vuyst et al. describing higher median viral
loads of high-risk HPV in HIV-positive women, regard-
less of HPV type [45]. HPV viral load possibly correlates
with the immune deficiency in these patients [10] and
with likelihood of persistent HPV infection [46]. The
highest viral burdens were found with HPV 33 in HIV-
positive women and HPV 56 in HIV-negative women.
HPV 16 had a relatively low viral load, though even at
low viral levels has high oncogenic potential [47,48].
Even though current HPV vaccines offer some cross-
protection against several HPV types [49], type-specific
analysis of HPV data remains important for informing
future HPV vaccine development and distribution. In
women attending a family planning clinic in Nairobi,
Kenya, less than 10% had HPV 16 and/or 18, and these
types were present in about 40% of HSIL lesions [50]. In
our study, HPV 16 and/or HPV 18 were present in
about 20% of study participants, while still in about 40%
of women with LSIL or HSIL. However, that most cervi-
cal lesions were negative for HPV 16 and/or 18, suggests
that other high-risk HPV types might play a more
important role in this context of female sex work. These
types appear of particular importance in HSIL lesions in
HIV-infected women [28]. It is also possible that the
specific oncogenic HPV types that contribute to the
development of cervical cancer in HIV-positive women
may differ from those in HIV-negative women [51].
It is difficult to ascertain to what degree the sample
obtained through snowballing methods is representative
of the FSW population in Mombasa. Though snowball
sampling is appropriate for locating difficult-to-reach
populations, as it is a non-random sampling method,
selection bias may occur. The investigators elected to
have a large sample size, in an attempt to mitigate such
effects. As a further limitation, information was missing
on both HIV and high-risk HPV types, which could
introduce bias. Such bias, however, is likely minimal as
the missing information can be assumed to be non-dif-
ferential in nature [52].
Patterns of HPV prevalence will likely alter the impact
of prophylactic HPV vaccination [53]. The extent of this
would be better understood if more information was
available on the natural history of dysplasia associated
with HPV types other than 16 and 18. The study popula-
tion described here is highly suited to prospective assess-
ment of this and related topics, given the considerable
burden on HPV disease in this population. Moreover,
previous cohorts in this study population have been feasi-
ble, with more than 90% cohort retention rates [54,55].
Conclusion
Given the common occurrence of high-grade cervical
lesions, especially in HIV-infected women, regular HPV
screening and follow-up is essential for prevention of
cervical cancer. Even though much is known about
these diseases and their optimal control, current mea-
sures to prevent HIV and HPV in this population are
clearly inadequate. The lack of control of these infec-
tions means that sex workers likely play a disproportion-
a t er o l ei nt r a n s m i s s i o nd y n amics of both infections in
the general population. Additional prevention measures,
especially higher population-level coverage with HPV
vaccine, are required.
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